Faculty Profile: Gabor Keitner, MD

Gabor Keitner
Gabor Keitner, MD
Professor of Psychiatry & Human Behavior
Psychiatry & Human Behavior
Work: +1 401-444-3932
Gabor Keitner's research interest is in the assessment of comprehensive treatments for mood disorders including pharmacotherapy, psychotherapy, and family therapy. He conducts pharmacological clinical trials and is an international authority on family therapy and combined (biological and psychosocial) treatments. He is also investigating the effectiveness of disease management models for difficult-to-treat depression and bipolar disorders.

Institutions

Rih

Research Description

1. Psychopharmacology - Clinical trials. In a recently completed double blind placebo controlled study we showed that augmenting antidepressants with risperidone in patients with difficult-to-treat depression led to a significantly higher remission rate, faster recovery, better odds of remission, and better quality of life than placebo augmentation. An ongoing study is evaluating the effectiveness of seroquel as a primary antidepressant.

2. Management of Depression – A pilot study is underway to evaluate the effectiveness of a depression disease management program (education, lifestyle changes, coping skills, social support) for those patients continuing to experience distressing depressive symptoms in spite of adequate antidepressant treatment.

3. Caregiver Burden – A pilot study is underway to test the effectiveness of a telephone delivered educational family support program for caregivers of patients with bipolar disorder.

4. Combined Pharmacological and Psychosocial Treatments for Patients with Mood Disorders - Analyses continue for completed studies that tested the relative benefit of adding individual and or family therapies to standard pharmacotherapy for depression and bipolar disorders. Adjunctive family therapy appears to be of meaningful benefit in both disorders.

5. Family Therapy/Interventions – Studies are in the process of being designed to test the benefit of adding a family intervention to the care/management of patients undergoing prostatectomy for prostate cancer and for patients with diabetes and depression.

Grants and Awards

Exemplary Psychiatrist Award, National Alliance for the Mentally Ill (NAMI), 1994, 1996

Outstanding Teaching Award in General Psychiatry, Brown University, 1996-97

Honorary Member of the Hungarian Psychiatric Association for contribution to Hungarian and international psychiatry, Jubilee Anniversary Meeting of the Hungarian Psychiatric Association, Budapest, January 2005.

Dean's Teaching Excellence Award, 2001

Affiliations

Royal College of Physicians and Surgeons of Canada, 1979
American Psychiatric Association (APA), 1980
Rhode Island Psychiatric Society of the American Psychiatric Association, 1980
American Orthopsychiatric Association, 1981 - 1984
American Family Therapy Association, 1984 - 1992
Association for Clinical Psychosocial Research, 1985
--Council Member 1994
International Society of Psychoendocrinology, 1985
International Family Therapy Association, 1987 - 1992
--Treasurer 1987-1991
Society for Psychotherapy Research, 1991
Family Systems Psychiatrists/APA, 1992
Fellowship, APA, 1994
Scientific Advisory Board of the National Depressive and Manic Depressive Association, 1997 - 2001
American Association for Geriatric Psychiatry, 1998
American Psychopathological Association – Fellow - 1999
International Society for Affective Disorders, 2002
World Psychiatric Association, Chair, Section of Family Research and Intervention - 2002
World Psychiatric Association, Member of Advisory Council to the Scientific Committee, 2003

Funded Research

ACTIVE SUPPORT:

Principal Investigator, "A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Licarbazepine 750-2000 mg/d combined with Risperidone in the Treatment of Manic episodes of Bipolar I Disorder over 6 Weeks and Extension."
Novartis Pharmaceutica. $140,355. 11/20/04 – 3/30/08.

Investigator, "Treatments for Psychogenic Nonepileptic Seizures (NES)."
W.C. LaFrance, M.D. (Principal Investigator).
National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS). $182, 578, 7/1/03-3/30/08.

Principal Investigator, "A Multi-Centre, Double-Blind, Randomized-Withdrawal, Parallel-Group, Placebo Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SRTM) As Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period." (Amethyst Study)
Astra Zeneca. $243,000. 1/04/06 – 12/30/07.

Investigator, "Management of Bipolar Illness, The MoBI Project."
Internally funded, Rhode Island Hospital, $30,000. 12/15/05-12/15/06.

PAST SUPPORT:

Principal Investigator, "Management of Depression."
Internally funded, Rhode Island Hospital, $30,000. 3/05-7/06.

Investigator, "CBASP Augmentation for Treatment of Chronic Depression."
Martin B. Keller, M.D., Principal Investigator.
National Institute of Mental Health (NIMH) $250,000 9/2002 – 6/2006

Principal Investigator, "Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to an Adequate Trial of an Antidepressant."
Janssen. $636,174. 2003 – 2005.

Principal Investigator, "Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients with Bipolar I Disorder with a Major Depressive Episode - CN138-146-027.
Bristol Myers Squibb $152,046 6/04 – 6/05.

Co-Principal Investigator, "Combined Treatment for Depressed Inpatients"
Ivan W. Miller, Ph.D., Principal Investigator.
NIMH $474,710 2/15/00-1/31/05

Principal Investigator, "A Double-Blind, Multi-Center, Extension Trial in Subjects with Major Depressive Disorder Who Participated in the Placebo-Controlled, Efficacy and Safety Trial of Org 33062 ER and Fluoxetine in Subjects with Major Depressive Disorder."
Organon, Inc. $62,650. 4/1/03 – 4/1/04.

Principal Investigator, "A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Efficacy and Safety Trial of Org 33062 ER and Fluoxetine in Subjects with Major Depressive Disorder."
Organon, Inc. $248, 038, 3/2003 – 3/2004.

Principal Investigator, "A Worldwide, Multicenter, Double-Blind, Parallel, Active-Controlled, Long Term Safety Study of MK-0869 in Outpatients with Major Depressive Disorder."
Merck. $362,070. 1/2002 – 1/2003.

Principal Investigator, "The Use of Mirtazapine in Reducing SSRI-Induced Sexual Side Effects."
Yale/Organon. $198,000. 3/1/2000.

Principal Investigator, "The Combination of Olanzapine and Fluoxetine in Treatment Resistant Depression without Psychotic Features."
Eli Lilly and Company. $83,000. 10/99 – 10/2000.

Principal Investigator, "An Open-Label Randomized Assessment of the Efficacy and Tolerability of Venlafaxine Extended Release in Serotonin-Selective Reuptake Inhibitor (SSRI) – Failure Patients with Major Depression."
Wyeth-Ayerst Laboratories. $87,000. 6/99 – 6/2000.

Principal Investigator, "A Double Blind Study of Two Doses of LL-759274 versus Paroxetine Hydrochloride and Placebo in the Treatment of Outpatients with Major Depressive Disorder."
Merck & Co. Inc.. $221,000. 6/99 – 6/2000.

Co-principal Investigator, "An Eight-Week, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of St. John's Wort in Outpatients with DSM-IV Major Depression."
Pfizer Pharmaceuticals. $85,000. 6/98 – 6/99.

Principal Investigator, "Olanzapine Versus Placebo in the Treatment of Bipolar Disorder, Mania or Mixed."
Eli Lilly and Company. $296,350. 5/98 – 5/99.

Co-principal Investigator, "A Prospective, Multi-Center Study Comparing the Safety and Efficacy of Nefazodone HCL to Cognitive Behavioral Therapy - Chronic Depression (CBT-CD) and Combined Nefazodone and CBT-CD for the Acute, Continuation and Maintenance Treatment of Chronic forms of Depression".
Martin B. Keller, M.D., Principal Investigator.
Bristol-Myers-Squibb. $1,000,000. 4/96-9/99.

Principal Investigator, "A Multi-Center, Placebo-Controlled Study of Relapse Prevention by Long-Term Treatment with the Recommended Dose Range of Remeron in Outpatient with Major Depressive Episode."
Organon, Inc. $217,185.00 6/97-5/98.

Principal Investigator, "Fluoxetine versus Sertraline and Paroxetine in Major Depression: Comparison of Discontinuation - Emergent Signs and Symptoms."
Eli Lilly and Company. $146,973 8/96-8/97.

Co-principal Investigator, "Double Blind Parallel Comparison of Sertraline and Imipramine in Outpatients with Concurrent DSMIII-R Major Depression and Dysthymia."
Martin B. Keller, M.D., Principal Investigator.
Pfizer Pharmaceuticals. $363,180. 1992-1997.

Co-principal Investigator, "Double Blind Parallel Comparison of Sertraline and Imipramine in Outpatients with Chronic DSMIII-R Major Depression."
Martin B. Keller, M.D., Principal Investigator.
Pfizer Pharmaceuticals. $364,680. 1992-1997.

Co-Principal Investigator (5%), "Family Treatment of Bipolar Disorder-Competitive Services Research Supplement."
Ivan W. Miller, Ph.D., Principal Investigator.
NIMH R01 MH48171. $579,390. 9/30/94-8/31/97.

Co-Principal Investigator (20%), "Family Treatment of Bipolar Disorder."
Ivan W. Miller, Ph.D., Principal Investigator.
NIMH R01 MH 48171. $2,196,753, 9/1/92-8/30/97.

Co-Principal Investigator (20%), "Matched vs. Mismatched Treatment for Depressed Inpatients."
Ivan W. Miller, Ph.D., Principal Investigator.
NIMH Grant R01 MH 44778. $1,360,825 4/1/90-3/30/95.

Co-Principal Investigator, "Randomized, Parallel group, Double-Blind, Dose-finding study of 3 different doses of Roxindole (EMD 62100) vs. Placebo in Outpatients Suffering from Major Depression."
Martin B. Keller, M.D., Principal Investigator.
EM Industries. $170,000. 1993-1994.

Investigator (0%), "Family-Child Study of Affective and Anxiety Disorders."
Arnold J. Sameroff, Ph.D., Principal Investigator.
NIMH R01 MH 44755-01 A1. $1,188,859, 10/01/89-9/30/94.

Co-Principal Investigator, "Suicide Ideation Scale Validation in Depressed Patients."
Ivan W. Miller, Ph.D., Principal Investigator.
Eli Lilly & Co.. $200,624, 9/1/91-8/30/92.

Principal Investigator, "Double Blind Comparison of Three Fixed Doses of Tandospirone in Outpatients with Major Depression."
Pfizer Pharmaceuticals. $125,000. 1/1/91-1/1/92.

Investigator, "DSM-IV Field Trial on Dysthymia."
M.B. Keller, Principal Investigator.
American Psychiatric Association. $15,000. 11/1/90-1/1/92.

Associate Investigator (10%) "Psychological Treatment of Depressed Inpatients."
Ivan W. Miller, Principal Investigator.
NIMH MH 35934. $296,392, 1/1/81-8/31/85

Principal Investigator, "Family Functioning and Affective Disorders in Different Cultures."
475-85-0004.
Social Sciences and Humanities Research Council of Canada. $1500. August 1985.